Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 9/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 9/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 9/20 | 0.38 |
| ▸ | BMPR1B | O00238 | 8/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313007 | 0.80 | TGFBR1 (0.39) | ADORA2AADORA1PTGDR2PTGS2BMPR1A | |
| SCHEMBL1106491 | 0.76 | KDM4E (0.44) | ADORA2AADORA1PTGDR2PTGS2BMPR1A | |
| SCHEMBL10119732 | 0.74 | PTGS2 (0.47) | ADORA2AADORA1PTGDR2PTGS2BMPR1A | |
| SCHEMBL20048155 | 0.74 | ADORA2A (0.44) | ADORA2AADORA1PTGDR2PTGS2BMPR1A | |
| SCHEMBL628269 | 0.74 | ADORA2A (0.38) | ADORA2AADORA1PTGDR2PTGS2BMPR1A | |
| SCHEMBL1106469 | 0.74 | PTGDR2 (0.42) | ADORA2AADORA1PTGDR2PTGS2BMPR1A | |
| SCHEMBL14757564 | 0.74 | ADORA2A (0.38) | ADORA2AADORA1PTGDR2PTGS2BMPR1A | |
| SCHEMBL506044 | 0.74 | ADORA2A (0.38) | ADORA2AADORA1PTGDR2PTGS2BMPR1A | |
| SCHEMBL28643070 | 0.74 | PTGS2 (0.47) | ADORA2AADORA1PTGDR2PTGS2BMPR1A | |
| SCHEMBL21483640 | 0.74 | P2RX3 (0.39) | ADORA2AADORA1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9487526-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| US-8742120-B2 | Methods of preparing factor xa inhibitors and salts thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110152530-A1 | METHODS OF PREPARING FACTOR XA INHIBITORS AND SALTS THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152530-A1 | METHODS OF PREPARING FACTOR XA INHIBITORS AND SALTS THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | ADORA2A 253/4885ADORA1 308/4885PTGDR2 283/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | ADORA2A 1531/4885ADORA1 1096/4885PTGDR2 2260/4885 |
| US-20110152530-A1 | METHODS OF PREPARING FACTOR XA INHIBITORS AND SALTS THEREOF | F12, TFPI, F11 | ADORA2A 3048/4885ADORA1 2429/4885PTGDR2 4345/4885 |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | ADORA2A 253/4885ADORA1 308/4885PTGDR2 283/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | ADORA2A 1531/4885ADORA1 1096/4885PTGDR2 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.